Egetis Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Egetis Therapeutics has a total shareholder equity of SEK318.6M and total debt of SEK111.2M, which brings its debt-to-equity ratio to 34.9%. Its total assets and total liabilities are SEK577.5M and SEK258.9M respectively.
Key information
34.9%
Debt to equity ratio
SEK 111.20m
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 129.90m |
| Equity | SEK 318.60m |
| Total liabilities | SEK 258.90m |
| Total assets | SEK 577.50m |
Recent financial health updates
Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?
Dec 07
Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?
Aug 20Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation
May 26We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate
Dec 21Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?
Jun 07Recent updates
Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?
Dec 07Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?
Aug 20Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation
May 26We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate
Dec 21Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?
Jun 07Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?
Jan 19Financial Position Analysis
Short Term Liabilities: EGTX's short term assets (SEK164.4M) do not cover its short term liabilities (SEK167.0M).
Long Term Liabilities: EGTX's short term assets (SEK164.4M) exceed its long term liabilities (SEK91.9M).
Debt to Equity History and Analysis
Debt Level: EGTX has more cash than its total debt.
Reducing Debt: EGTX's debt to equity ratio has increased from 0% to 34.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EGTX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: EGTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23.4% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 07:12 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Egetis Therapeutics AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Patrick Langstrom | ABG Sundal Collier Sponsored |
| Oscar Haffen Lamm | Bryan Garnier & Co |